Scarica l'app Stockscreener
2.25
7.14%
0.15
Precedente Chiudi:
$2.10
Aprire:
$2.1991
Volume 24 ore:
5,165
Relative Volume:
0.69
Capitalizzazione di mercato:
$81.41M
Reddito:
-
Utile/perdita netta:
$-59.51M
Rapporto P/E:
-2.0455
EPS:
-1.1
Flusso di cassa netto:
$-55.09M
1 W Prestazione:
-6.64%
1M Prestazione:
-6.25%
6M Prestazione:
-12.79%
1 anno Prestazione:
+7.14%
Intervallo 1D:
$2.1535
$2.26
Intervallo di 1 settimana:
$1.98
$2.40
Portata 52W:
$1.98
$4.48
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Nome
Armata Pharmaceuticals Inc
Settore
Industria
Telefono
310-655-2928
Indirizzo
4503 Glencoe Avenue, Marina del Rey, CA
Confronta ARMP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ARMP | 2.25 | 81.41M | 0 | -59.51M | -55.09M | -1.10 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-06-19 | Iniziato | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Borsa (ARMP) Ultime notizie
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update - GuruFocus.com
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - Quantisnow
Armata Pharmaceuticals FY2024 EPS Raised by HC Wainwright - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Armata Pharmaceuticals (NYSEAMERICAN:ARMP) - Defense World
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Armata Pharmaceuticals Reports $3M Revenue, Advances Key Clinical Trials in Q3 | ARMP Stock News - StockTitan
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given "Buy" Rating at HC Wainwright - MarketBeat
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - PR Newswire
Armata Pharmaceuticals Announces Structural Biology Publication - PR Newswire
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Decline in Short Interest - MarketBeat
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 2.2%Should You Sell? - MarketBeat
Armata Pharmaceuticals VP Richard Rychlik Departs with Benefits - TipRanks
10 Best Healthcare Stocks to Invest In (November 2024) - Securities.io
Armata Pharmaceuticals announces executive departure - Investing.com
Arkema S.A. (OTCMKTS:ARKAY) Sees Large Growth in Short Interest - MarketBeat
Comparing ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Confronting Oropouche: a new stage for Cuban science - Radio Cadena Agramonte
Alto Neuroscience's Market Cap Drops To US$358m Leaving Insiders With Losses - Simply Wall St
American Century Companies Inc. Purchases 8,841 Shares of Armstrong World Industries, Inc. (NYSE:AWI) - MarketBeat
The Attractiveness of Investing In Artiva Biotherapeutics Inc (ARTV) is Growing - Knox Daily
ANRO’s latest rating updates from top analysts. - Knox Daily
ARKO Corp. (ARKO) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Art’s-Way Manufacturing (NASDAQ:ARTW) Now Covered by StockNews.com - Defense World
Dimensional Fund Advisors LP Has $193.14 Million Position in Archrock, Inc. (NYSE:AROC) - Defense World
Your Safety First: What You Need to Know About Bionpharma’s Urgent Atovaquone Recall - MyChesCo
Building Materials Stocks Q2 Results: Benchmarking Armstrong World (NYSE:AWI) - Yahoo Finance
Aurora Biosynthetics launch set to revolutionise RNA Therapeutics - Manufactures Monthly
Amplia Therapeutics’ Drug Fast-Tracked by FDA - TipRanks
Atovaquone Oral Suspension Recall Issued Due to Bacterial Contamination Risks - AboutLawsuits.com
Burgundy Asset Management Ltd. Purchases 17,075 Shares of Armstrong World Industries, Inc. (NYSE:AWI) - MarketBeat
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023 - GuruFocus.com
New player in RNA manufacturing: Aurora Biosynthetics launches in Australia - Australian Manufacturing
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 11.1% in August - MarketBeat
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Quantisnow
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 133.3% in August - MarketBeat
Armata Pharmaceuticals Updates Progress and Corporate Presentation - TipRanks
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium - Longview News-Journal
ARMP Stock Earnings: Armata Pharmaceuticals Beats EPS for Q2 2024 - MSN
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Down 12.9% in July - MarketBeat
Dr. Deborah Birx Is Now The CEO Of Armata Pharmaceuticals - KossyDerrick
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Rating Reiterated by HC Wainwright - Defense World
HC Wainwright Brokers Raise Earnings Estimates for Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) - Defense World
HC Wainwright Analysts Boost Earnings Estimates for Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) - MarketBeat
Armata Pharmaceuticals' (ARMP) Buy Rating Reiterated at HC Wainwright - MarketBeat
Armata Pharmaceuticals Welcomes David House as New SVP of Finance - TipRanks
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - Quantisnow
ARMPArmata Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update - StockTitan
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 2.8% - MarketBeat
Armata Pharmaceuticals Inc Azioni (ARMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):